Two mitotic Cyclins, A and B, exist in higher eukaryotes, but their specialised functions in mitosis are poorly understood. Using degron tags we analyse how acute depletion of these proteins affects mitosis. Loss of Cyclin A in G2-phase prevents the initial activation of Cdk1. Cells lacking Cyclin B can enter mitosis and phosphorylate most mitotic proteins, because of parallel PP2A:B55 phosphatase inactivation by Greatwall kinase. The final barrier to mitotic establishment corresponds to nuclear envelope breakdown that requires a decisive shift in the balance of Cdk1 and PP2A:B55 activity. Beyond this point Cyclin B/Cdk1 is essential to phosphorylate a distinct subset mitotic Cdk1 substrates that are essential to complete cell division. Our results identify how Cyclin A, B and Greatwall coordinate mitotic progression by increasing levels of Cdk1-dependent substrate phosphorylation.
Main Text
Cdk1 phosphorylates over 1000 proteins 1, 2 within the brief 20-30 minute window of mitotic entry, triggering centrosome separation and chromosome condensation in prophase, followed by nuclear envelope breakdown (NEBD) and mitotic spindle formation in prometaphase, and the alignment of bi-oriented sister chromatids at the metaphase plate 3 . Binding of a Cyclin partner is critical for allosteric activation of CDKs. Two families of mitotic Cyclins, termed A and B, work with Cdk1 to orchestrate mitotic entry in higher eukaryotes 4, 5 . Despite the central importance of these proteins for cell cycle control, the functional specialisation of mammalian A and B-type Cyclins remains unclear. Following the depletion of maternal pools of early embryonic Cyclin A1 and B3, somatic mammalian cells express one A-type Cyclin, A2, and two B-type cyclins, B1 and B2.
Genetic depletion in mice suggests an essential role for Cyclin A2 for development, but not for embryonic fibroblast proliferation 6 . Depletion of Human Cyclin A2 by siRNA delays mitotic entry, and this is further enhanced by co-depletion of Cyclin B1 [7] [8] [9] . Likewise, work in mammalian cell extracts documented how Cyclin A synergises with Cyclin B to control the mitotic entry threshold at the level for Cdk1 activation 10 . A mechanism involving Plk1 activation has been suggested 11, 12 , although an essential role of Plk1 in the G2/M transition remains contentious 13 . Likewise, work in mammalian cell extracts documented how Cyclin A synergises with Cyclin B to control the mitotic entry threshold at the level for Cdk1 activation 10 . A confounding factor in the genetic analysis of Cyclin A2 has been its dual role in S-phase and mitosis 14 , making it difficult to directly investigate G2 specific defects.
Murine Cyclin B1 is essential for development 15 and critical for mitotic entry in early mouse embryos 16 4 within a single cell cycle. We have recently reported that a combination of AID- 24 and SMASh- 25 tags results in highly efficient induced degradation 26 , and applied this strategy to comprehensively analyse the functions of Cyclin A2 and B1 in a non-transformed, h-TERT immortalised human epithelial cell line, RPE-1 ( Figure S1 ). To further reduce the levels of B-type Cyclins in these cells we also generated a CRISPR based knock out of the CCNB2 gene encoding Cyclin B2 in the Cyclin B1 degron cells, and verified absence of Cyclin B2 by western blotting ( Figure S1D ). The homozygous Cyclin A2 and B1 double degron mAID-SMASh tag fusions (A2 dd , B1 dd ) allowed us to compare the depletion efficiency of the single and combined degron systems in these cells ( Figure S2 ). These results demonstrate that the individual degron tags were not sufficient to fully deplete the tagged Cyclins, likely due to their rapid synthesis rates. Activation of both degradation systems using the "DIA" cocktail (Dox/IAA for mAID and ASV for SMASh, see methods), on the other hand, was highly effective to trigger rapid degradation of either Cyclin that became undetectable after 2-4 hours of treatment. Quantification of this depletion experiment ( Figure 1A and B) shows 50% depletion within the first hour and an ultimate depletion to less than 5% of control protein levels within 2-4 hours.
Using this depletion system, we further analysed A2 dd , B1 dd and B1 dd /B2 ko cells by measuring the distribution of cell cycle phases in asynchronous cells, 24 hours after DIA treatment ( Figure 1C and Figure S3A ). Loss of Cyclin A2 caused an accumulation of the 4N population, but depletion of Cyclin B1 had little effect on the cell cycle phase distribution of RPE-1 cells. Furthermore, DIA treatment abolished cell proliferation in A2 dd cells, but only had a mild effect in Cyclin B1 dd cells as judged by a long-term proliferation assay ( Figure S3B ). RPE-1 cells lacking Cyclin B1 relied on Cyclin B2 for proliferation, because B1 dd /B2 ko cells showed an accumulation of 4N cells and decrease in proliferation following DIA treatment ( Figure 1C and S3). We next measured mitotic entry dynamics in cells lacking either Cyclin A2 or both B1 and B2 ( Figure 1D and E, Figure S4 ).
DIA treated A2 dd cells ceased to enter mitosis rapidly following drug addition, while lack of Cyclin B1 and B2 did not measurably affect the dynamics of mitotic entry. However, these cells had severe defects in mitotic progression and cell division (see below). We also tested, if Cyclin B3 could account for mitotic entry observed in the absence of Cyclin B1 and B2. However, we could not detect Cyclin B3 protein in these cells by immuno-blotting despite the presence of the mRNA of this Cyclin. Moreover, siRNA depletion of the Cyclin B3 mRNA in combination with DIA treatment of B1 dd /B2 ko cells did not appear to reduce the number of mitotic cells ( Figure S3C and D). Taken together, these results suggest that Cyclin A2 is essential to initiate mitosis and that B-type Cyclins are not required for mitotic entry.
Previous reports implicated Cyclin A2 in triggering M-phase via Cdk1 activation 7, 9 , but could not differentiate between knock-on effects of DNA replication problems and G2 specific functions of Cyclin A2. We took advantage of the A2 dd cells to address this question by performing G2 specific depletion of Cyclin A2. For this purpose, we used a PCNA-mRuby fusion 27 to identify cells 5 that were in G2 phase at the time of DIA treatment ( Figure 2A ). This assay revealed that DIA addition in G2 phase effectively blocked further progression into mitosis ( Figure 2B ), suggesting that either the presence, or new synthesis of Cyclin A in this cell cycle phase is required for mitotic entry. To further support this notion, we performed EdU pulse labelling at the time of DIA treatment, followed by fixation and CENP-F immuno-fluorescence five hours later to mark cells that were in G2 phase (CENP-F positive/EdU negative) when Cyclin A2 degradation began ( Figure S5 ). This resulted in an accumulation of cells that had been in G2 phase at the time of DIA treatment, further supporting a G2-specific role for Cyclin A2. Inhibition of Wee1, a kinase that inhibits Cdk1 in interphase, was sufficient to overcome this block and resulted in resumption of mitotic entry with kinetics comparable to the controls ( Figure 2C ). Once the G2 block was overcome by Wee1 inhibition, cells lacking Cyclin A could form a metaphase spindle and underwent chromosome segregation and cell division ( Figure 2D and E). Thus, Cyclin A does not appear to play an essential role in mitosis once Cdk1 is activated. Figure 3C shows a typical example of mitotic progression in cells with or without B-type cyclins (see also Videos 01 and 02). While cells lacking cyclin B can clearly initiate chromosome condensation, NEBD and spindle formation they fail to segregate their sister chromatids and exit mitosis with a single fragmented nucleus.
A simple explanation for this failed mitotic exit could be the early degradation of Cyclin A2 by the APC/C that is independent of the spindle assembly checkpoint. However, we observed a distinct mitotic defect in cells lacking Cyclin B1/2 ( Figure 3D -F) even in the presence of a APC/C inhibitor cocktail 28 . Thus, mitotic cells expressing only Cyclin A2, but lacking B-type Cyclins assemble a bipolar, but often malformed spindle, and fail to align their chromosomes on the metaphase plate.
Overall, we observed an enrichment in prophase, and prometaphase (or defective metaphase) after DIA treatment and APC/C inhibition, but failed to identify DIA treated cells with a clear metaphase alignment ( Figure 3F ). Exposure to ice cold medium revealed intact K-fibres in DIA treated B1 dd /B2 ko cells, and re-exposure to warm medium resulted in the reformation of a disorganised spindle with extended astral microtubules ( Figure 3G ). We also used the centromere/kinetochore markers CenpA and CenpB to asses bi-orientation and segregation of sister chromatids ( Figure S7 ).
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The markedly reduced distance between sister centromeres following DIA treatment suggests lack of tension. Moreover, we frequently observed unseparated centromere pairs in cells that were exiting mitosis, as judged by attempted furrow formation, indicating that Separase activation and/or MT force generation was impaired in these cells. These distinct phenotypes suggest that, while Cyclin B is required for specific regulatory events to coordinate the metaphase/anaphase transition, it is not essential for the establishment of the mitotic state. Accordingly, we observed only a small decrease in the level of Cdk substrate phosphorylation following DIA treatment as judged by quantitative immuno-fluorescence ( Figure 3E ).
To further quantity the contribution of Cyclin B to mitotic phosphorylation events and identify
Cyclin B specific substrates, we compared the phospho-proteome in control and DIA treated B1 dd /B2 ko cells ( Figure 4A , S8). We quantified differences in phosphorylation in 5,760 phosphorylation-sites (Supp. B depletion causes a significant but relatively minor effect on the majority of mitotic phosphorylations, but causes a more dramatic reduction in phosphorylation of only ~5% of the phospho-proteome, and ~8.4% of the proline-directed sites (271 / 3,192). These substrates were predominantly cytoskeletal and chromatin associated proteins ( Figure 4B ). A more detailed network analysis ( Figure   S9 ) identified a variety of mitosis associated processes that involve Cyclin B specific substrates, including chromosome structure, MT dynamics and cytokinesis.
We validated this data set experimentally by analysing the localisation of a group of Cyclin B specific targets identified in the screen. Figure 4G ). CPC mis-regulation also correlates with the significant decrease in Histone H3 S10 phosphorylation, a target of AurB kinase activity that we observed (Supp. Table 2 ). Likewise, the reduction of phosphorylation of CdcA2, Top2B and Tpx2 following DIA treatment correlated with changes mitotic localisation ( Figure S10 ), further validating the significance of our proteomic data set. Figure 4H and I, and S11A).
If the inhibition of PP2A:B55 by phosphorylated Ensa/ARPP19 is responsible for establishing mitosis in the absence of Cyclin B, simultaneous depletion of B-type Cyclins and the Greatwall pathway should ultimately prevent cells from entering mitosis. To test this hypothesis, we depleted Ensa and ARPP19 from B1 dd /B2 ko cells ( Figure S11A ) and monitored mitotic progression by timelapse microscopy ( Figure 5A , Videos 05 and 06). Depletion of Ensa/ARPP19 did not prevent mitotic entry, but resulted in sister chromatid misalignment and cytokinesis defects, as previously reported for cells lacking Greatwall
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. Cyclin B depletion by DIA treatment caused similar mitotic exit phenotypes as described above ( Figure 3A-D) . Surprisingly, cells with simultaneous depletion of Ensa/ARPP19 and Cyclin B appeared able to enter prophase, as judged by cell rounding, centrosome separation and compaction of the nucleus. However, these cells did not undergo NEBD and often remained in this prophase-like state for a prolonged period of time, before reverting to interphase ( Figure 5A , bottom panel, Figure S11C , Video 06).
These data suggest that cells can enter prophase in the absence of Cyclin B and with high PP2A:B55 activity, but fail to move past NEBD. To further substantiate this observation we analysed the mitotic state following Greatwall/Cyclin B and Ensa/ARPP/Cyclin B depletion ( Figure   S11A , B) in fixed cells by immuno-fluorescence (see representative images in Figure 5B ). The mitotic index, as judged by cell rounding, centrosome separation and chromosome condensation, was only mildly reduced in the co-depleted cells ( Figure S11D ). However, more than 90% of mitotic cells lacking both Cyclin B and Greatwall or Ensa/ARPP19 failed to undergo NEBD as judged by Lamin A/C staining ( Figure 5C ). Our results can be summarised by a mathematical model ( Figure 5E , F and S12) that suggests a simple ordering mechanism for mitotic entry, based on the increasing requirement for Cdk1-Cyclin 8 activity, and increasing levels of sensitivity to the antagonising phosphatase activity. This fits well with a similar biochemical model for the ordering of mitotic exit 23, 35 . Cyclin A in G2 phase is critical to trigger mitosis by counteracting Wee1 and is sufficient to phosphorylate an early set of Cdk1
substrates that cause the initiation of prophase. These substrates are likely to be poor PP2A:B55 targets and therefore require a low threshold of Cdk1:Cyclin activity. In the absence of Greatwall and Cyclin B, cells remain in this prophase state for several hours before reverting back to interphase.
This observation is supported by our recent report of a latent stable steady state that can be reached in prophase 36 .
The next step in mitotic establishment, NEBD and transition to prometaphase, requires either Greatwall dependent PP2A:B55 inactivation, or Cyclin B dependent increase in the levels of Cdk1 activity to phosphorylate the bulk of intermediate mitotic substrates. Our finding that Cyclin B and Greatwall act in parallel explains how this regulatory network is designed to allow buffering against fluctuations in kinase and phosphatase activity during mitotic entry. It also explains the lack of entry phenotypes in Greatwall and Cyclin B depleted cells.
Our study defines a final set of late substrates that strictly require Cyclin B dependent Cdk1 activity. These phosphorylation events are critical to initiate anaphase and cell division. We assume that these phospho-sites are highly sensitive to Cdk1 counteracting phosphatases and therefore require higher levels of Cdk1:Cyclin activity. However, it remains to be seen, what ultimately determines this specific requirement for B-type Cyclins. Moreover, future work will need to establish, why Cyclin B cannot compensate for Cyclin A2 as the mitotic trigger. The rapid induced degradation system that we report here will be a helpful tool to further address these questions for a better understanding of mammalian cell cycle control mechanisms. Upon inhibition by the protease inhibitor, asunaprevir (Asv), the tag remains on the target protein and exposes it to the cellular degradation machinery, while the old protein is depleted depending on its specific half-life. The AID tag relies on the expression of the plant F-box protein TIR1 that combines with mammalian Skp1 and Cul1 to form a functional SCF E3 ligase. It is activated to recognise and ubiquitylate the AID degron tag upon stimulation by the hormone Auxin (IAA). In the case of the tag combination newly synthesised proteins are depleted by the two independent degradation systems, while old proteins are destabilised by the mAID tag. (B) Comparison of protein degradation efficiency using different degrons. Cells were incubated for inicated time periods with Asv or DOX/IAA or both (DIA) then collected for western blot analysis. Doxycyclin was added 2 hours before addition of IAA or ASV/IAA. To determine protein degradation, either cyclin A2 or cyclin B1 were probed as indicated . Anti-myc antibody was used to check OsTIR1-myc expression. Asteriks indicates non-specific protein cross reacting with the Cyclin B1 antibody. Figure 3A and Figure S8 Experimental scheme for phosphorylation-proteomic analysis (A) Cell synchronisation scheme: To obtain an optimal enrichment in mitotic cells we presynchronised B1 dd /B2 ko cells by serum starvation for 48 hours followed by a release in thymidine for 24 hours. Cells were then released into S-phase in the presence or absence of DIA and blocked in mitosis by the addition of ProTame. Mitotic cells were collected by shake-off 12 hours following release. (B) Phosphoproteomics workflow. Protein extracts were prepared from the indicated cells, digested with trypsin and labelled with 6-plex TMT reagents. The TMT-labelled peptides were then mixed and subjected to fractionation by high pH reverse phase into 24 fractions. From each fraction, 95% was taken for phosphoenrichment and 5% retained for analysis of unmodified peptides. For phosphoenrichment, the 24 fractions were combined into a total of 16 fractions. Samples (unmodified and phosphoenriched) were then analysed by LC-MS/MS on an Orbitrap Fusion instrument using synchronous precursor selection (SPS). This analysis resulted in detection of 11,234 phosphorylation sites, of which 5,670 were quantitated. The number of class I sites are indicated in brackets (site localisation probability > 0.75)." 
B) Supplementary Tables
Supplementary Table 1 All detected phosphorylation sites. Columns include protein identifiers, the site localisation probabilities, positions in protein, positions in peptide sequence, the identification score, the posterior error probability (PEP), the localisation score, the normalised TMT reporter intensities for the phosphorylated peptides, the normalised TMT reporter intensities for the unmodified protein, ratio of phosphorylated/unmodified, the mean fold change (3 biological replicates), the p-value (t-test, uncorrected), and columns indicating whether several linear motifs are found in the phosphorylated peptide sequence (e.g. CDK consensus motif, etc.)
Supplementary Table 2
Significantly changing phosphorylation sites as determined by 2x-fold change and 0.05 p-value cutoffs. Columns include protein identifiers, the site localisation probabilities, positions in protein, positions in peptide sequence, the identification score, the posterior error probability (PEP), the localisation score, the normalised TMT reporter intensities for the phosphorylated peptides, the normalised TMT reporter intensities for the unmodified protein, ratio of phosphorylated/unmodified, the mean fold change (3 biological replicates), the p-value (t-test, uncorrected), and columns indicating whether several linear motifs are found in the phosphorylated peptide sequence (e.g. CDK consensus motif, etc.)
C) Material and Methods

Tissue Culture and Chemical Reagents
hTERT RPE-1 cells were obtained from ATCC (cat. CRL-4000) and were grown at 37°C with 5% CO2 in DMEM/F12 (Sigma-Aldrich) media containing 10% fetal bovine serum (FCS) and 1% penicillin-streptomycin.
Drugs used for this study and working concentrations were: ). The reaction was performed on a PCR Stratagene MX3005P system. Fold change in expression over control was calculated using the delta-delta Ct method (4).
Proliferation assay
1000 cells per well were seeded and treated or not with 1µg/mL of doxycycline, 3µM of Asv and 500µM of IAA for 1 week then cells were fixed and stained with a solution containing 0.05% crystal violet (Sigma-Aldrich), 1% formaldehyde (Sigma-Aldrich), 1% methanol in PBS for 10min.
for the identification. Raw MS files and MaxQuant output files underpinning the mass spectrometry-based phosphoproteomics data shown are available through the ProteomeXchange partner PRIDE (accession PXD01210)
Post-MaxQuant processing was performed using R (version 3.5.0). Potential contaminant proteins and hits to the reverse database were removed from consideration. TMT reporter were normalised by the median protein TMT reporter intensities to correct for unequal loading and also corrected for isotope contamination. Phosphorylation site ratios were then calculated for each of the three biological replicates and normalised to the ratios measured for the total protein. Fold-change cutoffs at x ̅ ± 1.96 * s were determined by modelling log ratios as a normal distribution. Motif analysis was performed by mapping regular expressions downloaded for phosphorylation consensus motifs from ELM.
Functional classification of the candidates.
Outliers were analysed for biological process ontology. Annotations were extracted from the Gene Ontology database using QuickGO. Only qualifier ECO:0000269 experimental evidence used in manual assertion was considered. Biological process ontology verified by direct assay or mutant phenotype from Uniprot database was used to complement the protein classification.
Protein interaction map.
The interactome was built from human protein-protein interaction (PPI) databases. All Outliers were considered to build a PPI map using the software Cytoscape 3.5.1. Human PPIs from databases were retrieved using the plugin Bisogenet. Small-scale studies were considered and in vivo interactions or PPIs from direct complexes were displayed. The PPI map was complemented using data concerning protein complexes obtained from Uniprot and Corum ( http://mips.helmholtzmuenchen.de/corum/ ). Only PPIs relevant or possibly related to mitosis and proteins present in several protein complexes were shown.
Mathematical modelling of mitotic substrate phosphorylation.
We have extended our previous model (8) requires CycB:Cdk1 activity. We used nonlinear ordinary differential equations to describe the rate
